Drug Trial Radar · NCT02542384
A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
Last checked: Nov 19, 2026Latest source record: May 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
451
Actual
Start
Sep 2015
Primary completion
Apr 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study schedule is comprised of a 14-day Screening Period, a treatment period and an observation period. All eligible subjects will be randomized into one of 3 treatment groups (1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously prior to surgery, and at specific time intervals post surgery. Additional rescue pain and anti-nausea medication will be made available. Post surgical changes in pain intensity, nausea and vomiting will be assessed.
Conditions
- Post Abdominal Surgery Pain
Interventions
CR845 IV 1 mcg/kgDrug
CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.
CR845 IV 0.5 mcg/kgDrug
CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Placebo IVDrug
Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours. Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Primary outcomes
What the sponsor says the trial is designed to measure.
- A comparison of the change in Pain Intensity over time using the Numeric Rating ScaleTime frame: 24 hours
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Sheffield, Alabama
Cara Therapeutics Study Site
New Haven, Connecticut
Cara Therapeutics Study Site
Bradenton, Florida
Cara Therapeutics Study Site
Gainesville, Florida
Cara Therapeutics Study Site
Maitland, Florida
Cara Therapeutics Study Site
Miami Gardens, Florida
Cara Therapeutics Study Site
Pensacola, Florida
Cara Therapeutics Study Site
St. Petersburg, Florida
Cara Therapeutics Study Site
Chicago, Illinois
Cara Therapeutics Study Site
Boston, Massachusetts
Cara Therapeutics Study Site
Camden, New Jersey
Cara Therapeutics Study Site
Neptune City, New Jersey
Cara Therapeutics Study Site
Durham, North Carolina
Cara Therapeutics Study Site
Cleveland, Ohio
Cara Therapeutics Study Site
Columbus, Ohio
Cara Therapeutics Study Site
Pittsburgh, Pennsylvania
Cara Therapeutics Study Site
Chattanooga, Tennessee
Cara Therapeutics Study Site
Bellaire, Texas
Cara Therapeutics Study Site
Fort Worth, Texas
Cara Therapeutics Study Site
Houston, Texas
Cara Therapeutics Study Site
Plano, Texas
Cara Therapeutics Study Site
San Antonio, Texas
Cara Therapeutics Study Site
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.